CA2278152A1 - Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate - Google Patents

Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate Download PDF

Info

Publication number
CA2278152A1
CA2278152A1 CA002278152A CA2278152A CA2278152A1 CA 2278152 A1 CA2278152 A1 CA 2278152A1 CA 002278152 A CA002278152 A CA 002278152A CA 2278152 A CA2278152 A CA 2278152A CA 2278152 A1 CA2278152 A1 CA 2278152A1
Authority
CA
Canada
Prior art keywords
methotrexate
disease
autoimmune
bystander
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002278152A
Other languages
English (en)
Inventor
Ahmad Al-Sabbagh
Howard L. Weiner
Patricia A. Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2278152A1 publication Critical patent/CA2278152A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002278152A 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate Abandoned CA2278152A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
US60/036,722 1997-01-24
PCT/US1998/001648 WO1998032451A1 (fr) 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Publications (1)

Publication Number Publication Date
CA2278152A1 true CA2278152A1 (fr) 1998-07-30

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002278152A Abandoned CA2278152A1 (fr) 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (fr)
JP (1) JP2001511134A (fr)
KR (1) KR20000070460A (fr)
AU (1) AU6648898A (fr)
BR (1) BR9807112A (fr)
CA (1) CA2278152A1 (fr)
HU (1) HUP0001960A2 (fr)
IL (1) IL131025A0 (fr)
NO (1) NO993600L (fr)
WO (1) WO1998032451A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3993169B2 (ja) 2002-02-11 2007-10-17 アンタレス・ファーマ・インコーポレーテッド 皮内注射器
JP5216328B2 (ja) 2005-01-24 2013-06-19 アンタレス ファーマ インコーポレイテッド あらかじめ充填された針補助シリンジジェット式注射器
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
WO2007131013A1 (fr) 2006-05-03 2007-11-15 Antares Pharma, Inc. Injecteur de reconstitution à deux étages
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
EP2268342B1 (fr) 2008-03-10 2015-09-16 Antares Pharma, Inc. Dispositif de sécurité pour injecteur
EP3581224A1 (fr) 2008-08-05 2019-12-18 Antares Pharma, Inc. Injecteur à dosage multiple
CN102612381B (zh) 2009-03-20 2015-09-09 安塔瑞斯制药公司 危险试剂注入系统
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
WO2013134244A2 (fr) 2012-03-06 2013-09-12 Antares Pharma, Inc. Ampoule-seringue à caractéristique de force de rupture
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
ES2969984T3 (es) 2013-02-11 2024-05-23 Antares Pharma Inc Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida
JP6030803B2 (ja) 2013-03-11 2016-11-24 アンタレス・ファーマ・インコーポレーテッド ピニオンシステムを有する用量注射器
WO2014165136A1 (fr) 2013-03-12 2014-10-09 Antares Pharma, Inc. Seringues pré-remplies à volume constant et leurs trousses
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2014164285A2 (fr) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite
WO2016044095A1 (fr) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation
WO2021236518A1 (fr) 2020-05-19 2021-11-25 IRR, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359783B2 (fr) * 1987-06-24 2002-04-17 Autoimmune, Inc. Traitement de maladies auto-immunitaires par administration orale d'auto-antigenes
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
JPH05507501A (ja) * 1990-09-06 1993-10-28 リックスウーニーベルシテイト・テ・ウットレヒト リンパ球応答と免疫関連疾患との阻害剤
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
AU5960096A (en) * 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t ce lls
DE69627855T2 (de) * 1995-06-13 2004-03-11 Nippon Meat Packers, Inc. Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel

Also Published As

Publication number Publication date
EP0994717A1 (fr) 2000-04-26
EP0994717A4 (fr) 2000-07-26
WO1998032451A1 (fr) 1998-07-30
NO993600L (no) 1999-09-23
AU6648898A (en) 1998-08-18
NO993600D0 (no) 1999-07-23
HUP0001960A2 (hu) 2000-10-28
IL131025A0 (en) 2001-01-28
JP2001511134A (ja) 2001-08-07
KR20000070460A (ko) 2000-11-25
BR9807112A (pt) 2001-09-18

Similar Documents

Publication Publication Date Title
CA2278152A1 (fr) Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate
US5935577A (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
AU720695B2 (en) Bystander suppression of autoimmune diseases
WO1998032451A9 (fr) Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate
US6645504B1 (en) Bystander suppression of type I diabetes by oral administration of glucagon
Harrison et al. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes
Krause et al. Immunomodulation of experimental autoimmune diseases via oral tolerance
AU695883B2 (en) Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines
US20010007758A1 (en) Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
AU686797B2 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
WO2001089557A2 (fr) Methodes de prevention des accidents vasculaires cerebraux moyennant l'induction d'une tolerance a e-selectin
Virella et al. Organ-specific autoimmune diseases
US20040115217A1 (en) Bystander suppression of autoimmune diseases
JP2001502306A (ja) インシュリン依存性糖尿病の処置方法および組成物
Benson Efficacy and mechanisms of oral tolerance to myelin basic protein in relapsing experimental autoimmune encephalomyelitis
HAFLER et al. I. OVERVIEW OF HUMAN AUTOIMMUNE DISEASE

Legal Events

Date Code Title Description
FZDE Discontinued